Dr. Hochhaus on TFS With Nilotinib in Patients With CML
Andreas Hochhaus, MD, professor of Internal Medicine, Hematology and Oncology, interim head of the Department of Hematology and Medical Oncology, University Medical Center Jena in Germany, discusses results of the phase II ENESTFreedom study, which examined treatment-free survival (TFS) in patients with chronic myeloid leukemia (CML) who received frontline nilotinib (Tasigna).
Andreas Hochhaus, MD, professor of Internal Medicine, Hematology and Oncology, interim head of the Department of Hematology and Medical Oncology, University Medical Center Jena in Germany, discusses results of the phase II ENESTFreedom study, which examined treatment-free survival (TFS) in patients with chronic myeloid leukemia (CML) who received frontline nilotinib (Tasigna).
This prospective, nonrandomized study was designed to analyze TFS in 190 patients who continued on nilotinib following frontline treatment with the agent. When it was determined that patients maintained a deep molecular response, treatment with nilotinib was discontinued. At a 48-week follow-up, 51.6% of patients demonstrated deep molecular response and did not re-initiate treatment.
This was the study's primary endpoint, which demonstrates the feasibility of TFR following frontline nilotinib, Hochhaus explains.
<<<
